Know Cancer

forgot password

Proteome-based Personalized Immunotherapy of Malignant Brain Tumors

Phase 2/Phase 3
18 Years
70 Years
Open (Enrolling)

Thank you

Trial Information

Proteome-based Personalized Immunotherapy of Malignant Brain Tumors

The trial will include 60 cases of unresectable recurrent glioblastoma multiforme (GBM)
after two lines of standard chemotherapy and complete course of radiotherapy.

The first line therapy of GBM involves allogeneic haploidentical hematopoietic stem cells
(HSCs), dendritic vaccine (DV) and cytotoxic lymphocytes (CTLs).

HSCs are used to stimulate individualized adoptive immune response, to affect tumor cells
(TCs) toxically and to regulate tumor stem cells (TSCs) targeted in order to suppress their
reproductive and proliferative potential. To obtain HSC the donor receives 8 subcutaneous
administrations of granulocyte colony-stimulating factor (G-CSF) with 8-10 hours interval
for 4 days. The first three days a single dose is 2.5 mcg per 1 kg weight, the last day the
dose is doubled. The stem cells are harvested at day 5. Red blood cells are withdrawn by
centrifuging. The content of cell markers is evaluated by flow cytometry. The result is
assessed after cytoconcentrate enrichment and removal of mature cells and plasma from it.
The preparation is stored in tubes per 4 ml with cryoprotector and 10% poliglucin solution.
Stem cell proportion is no less than 0.5x106 CD34+, and lymphocytes proportion is no less
than 0.5x109 per one administration.

The sample of brain tumor is obtained through stereotaxic/ endoscopic/ open biopsy from all
patients included into the trial. The TCs and TSCs are immunochemically isolated from GBM
biopsy sample. One part of tumor sample is used for standard histological, cytological and
immunochemical testing, while tumor cells (TCs) and tumor stem cells (TSCs) (CD133+) are
isolated from the other part.

Dendritic cells are isolated from peripheral blood mononuclear cells and cultured. Tumor
sample provides tumor specific antigens to prepare DV.

Preparation of CTLs aims to enhance cytotoxic effect on tumor due to great number of
circulating CTLs. CTLs are isolated from about 100 ml of peripheral blood after 3 DV
administrations, and of them dendritic cells (DCs) are grown. Then, peripheral blood is
repeatedly taken, and lymphocytes are isolated. The CTLs are co-cultured with DCs loaded
with tumor antigens (first line therapy) or recombinant proteins identical to key
oncospecific proteins (second-line therapy) for several times to expand their number
(108-109). Their immunophenotype is detected and CTLs are cryopreserved. The first
stimulation of CTLs with DCs lasts 6-8 days, the second lasts 2-4 days, next 2 days the
lymphocytes are stimulated for the third and fourth time. And then the received lymphocytes
are stimulated by IL-2 for 2 days.

Six months after the first line therapy completion the efficiency is evaluated and the
cohort demonstrating efficiency continues the therapy, while cohort demonstrating no
efficiency will continue the trial with the second line therapy.

The second line therapy arm (active comparator arm) uses DV with recombinant proteins
identical to key oncospecific proteins, autologous CTLs and autologous HSCs with modified

Autologous HSCs are received from the trial participant as described previously. Cell
preparation of HSC for active comparator arm is obtained of the cytoconcentrate of
autologous mononuclear cells of peripheral blood after mobilization as specified for
experimental arm. Tumor specific antigens for active comparator group are provided by tumor
tissue of the patient.

TCs and TSCs as well as HSCs of the patient undergo complete transcriptome mapping and gene
expression profiling (CTMGEP) and proteome mapping and protein profiling (PMPP). Key (3 or 4
proteins with maximal normalized intensity) oncospecific proteins (OSP) are determined
according to proteome testing of TCs, while proteome profiling of TSCs and use of databases
of protein-protein relations permit detection of intracellular signal transduction pathways
(ISTP) unaffected by carcinogenesis and capable of regulation. Also, receptor membrane
targets to affect these signal pathways (acceptor membrane proteins) are detected, as well
as proteins that are able to activate them (protein ligands). CTMGEP of TSCs confirms
diagnosed functional ISTP. Mathematical modeling of CTMGEP and comparison with Affymetrix
GeneChip Human genome U133A Array data reveals perturbagens able to chemically induce HSCs
and to modify their proteome profile in order to provide secretion of requisite protein
ligands. The database analysis permits understanding of how changes in gene expression
induced by a low-molecular agent or micro RNA corresponds with the changes observed in the
examined profile. If correspondence is significant, it is supposed, that the agent or
similar agents can initiate the effect. If anticorrelation is significant, the agent is
supposed to initiate an opposite effect in gene expression modification. The transcriptome
of HSCs is modified by co-culturing mononuclear cells with perturbagens. Their biological
efficiency is evaluated in vitro in Homunculus bioreactor. Then preparation is stored as
described previously.

Individual DV is prepared from the leukoconcentrate of peripheral blood of the patient. The
lymphocytes are isolated, cultured with G-CSF and interleukin-2, conditioned by
tumor-specific antigens, TNF-α and PGE2 for 48 hours and loaded with recombinant proteins
identical to key tumor-specific antigens detected at proteomic testing of TCs. Basic
mechanism of individual DV immune effect is elaboration of tumor toxic lymphocytes by the
organism of the patient.

CTLs are obtained as described previously. The intervention is described in the appropriate

Toxicity will be evaluated according to CTC-NCI criteria. Efficiency is assessed according
to the following criteria:

1. Complete effect - -full disappearance of all tumor foci

2. Partial effect - -reduction of tumor size and/or metastatic foci by no less than 50%
and no signs of new neoplasms

3. Stabilization - reduction of tumor foci size by less than 50% and no signs of new

4. Progress - growth of tumor foci during the therapy. In case of mosaic effect, when part
of foci progresses and part is stable or reducing, the therapy is continued but the
cases are analyzed outside the context "Response to the therapy"

Inclusion Criteria:

- Morphologically confirmed glioma (in case of relapse and impossibility of biopsy,
diagnosis based on radiological and other diagnostic methods)

- Refractory to the first and following conventional lines of chemo- and radiotherapy,
if their removal is impossible.

- Glioblastoma relapses after at least one line of conventional chemo- and
radiotherapy, if their removal is impossible

- Availability of HLA partially compatible related donor

- Life expectancy of no less than 3 months

- Absence of severe decompensated organ dysfunction

- Informed consent of the patient or their parents

- Informed consent of the donor

Exclusion Criteria:

- Failure to meet one of the inclusion criteria

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

All cause mortality

Outcome Time Frame:

2 years

Safety Issue:


Principal Investigator

Andrey S. Bryukhovetskiy, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

ZAO "NeuroVita Clinic of Interventional and Restorative Neurology and Therapy"


Russia: Ethics Committee of FGBU "Federal Research Center for Specialized Types of Medical Care and Medical Technologies" of FMBA

Study ID:




Start Date:

December 2012

Completion Date:

December 2017

Related Keywords:

  • Glioblastoma
  • Glioblastoma, recurrent glioblastoma
  • Glioblastoma